Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus

被引:69
作者
Rosei, EA [1 ]
Rizzoni, D [1 ]
Muiesan, ML [1 ]
Sleiman, I [1 ]
Salvetti, M [1 ]
Monteduro, C [1 ]
Porteri, E [1 ]
机构
[1] Univ Brescia, Chair Internal Med, Dept Med & Surg Sci, Brescia, Italy
关键词
adhesion molecules; blood pressure; candesartan; clinical trials; diabetes mellitus; enalapril; hypertension;
D O I
10.1097/00004872-200502000-00027
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective Circulating adhesion molecules may have a prognostic significance as markers of endothelial damage. Drugs which inhibit the renin-angiotensin system may be effective in reducing circulating or tissue adhesion molecules, albeit data available are scarce. The aim of the study was to investigate the effects of an angiotensin-converting enzyme (ACE) inhibitor, enalapril and a highly selective angiotensin receptor blocker, candesartan cilexetil, on circulating adhesion molecules in a large sample of patients with non-insulin-dependent diabetes mellitus (NIDDM). The study was comparative, multicenter, randomized and double blind, with two parallel groups. Patients and methods NIDDM patients with a diagnosis of mild (grade 1) essential hypertension were included in the study, at the end of a 2-week placebo run-in period. The primary end-point of the study was to evaluate changes of intercellular adhesion molecule-1 (ICAM-1) plasma levels during treatment. The secondary end-points were: changes in vascular cells adhesion molecule-1 (VCAM-1), von Willebrand factor (vWF), fibrinogen and plasminogen activator inhibitor-1 (PAI-1) circulating levels and of urinary albumin excretion rate (AER) as well; 129 patients were randomized: 66 in the candesartan group and 63 in the enalapril group, 118 of them completed the scheduled 24-week treatment period. Results Candesartan and enalapril equally reduced circulating level of ICAM-1 and exerted comparable effects on changes of other adhesion molecules and coagulation factors. A similar blood pressure-lowering effect was observed with the two drugs (candesartan: from 148/90 +/- 11/8 to 132/82 +/- 12/7 mmHg, P < 0.01, enalapril: from 148/91 +/- 12/8 to 131/85 +/- 14/6 mmHg, P < 0.01). Candesartan was more effective than enalapril in the reduction of albuminuria (P < 0.05 between treatments), although urinary protein excretion can be considered normal in the majority of patients. The two drugs were comparable in terms of adverse events reported. Conclusion Candesartan and enalapril showed similar effects on blood pressure and on circulating adhesion molecules. In this study urinary protein excretion was reduced more by candesartan. (C) 2005 Lippincott Williams Wilkins.
引用
收藏
页码:435 / 444
页数:10
相关论文
共 38 条
[11]   Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension [J].
DeSouza, CA ;
Dengel, DR ;
Macko, RF ;
Cox, K ;
Seals, DR .
AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (12) :1335-1341
[12]   Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities [J].
Ferri, C ;
Desideri, G ;
Baldoncini, R ;
Bellini, C ;
De Angelis, C ;
Mazzocchi, C ;
Santucci, A .
DIABETES, 1998, 47 (04) :660-667
[13]   Endogenous insulin modulates circulating endothelin-1 concentrations in humans [J].
Ferri, C ;
DeMattia, G ;
Bellini, C ;
Santucci, A ;
Desideri, G .
DIABETES CARE, 1996, 19 (05) :504-506
[14]   Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria [J].
Gasic, S ;
Wagner, OF ;
Fasching, P ;
Ludwig, C ;
Veitl, M ;
Kapiotis, S ;
Jilma, B .
AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (02) :217-222
[15]   Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension:: the effect of treatment with ACE inhibitors [J].
Hlubocká, Z ;
Umnerová, V ;
Heller, S ;
Peleska, J ;
Jindra, A ;
Jáchymová, M ;
Kvasnicka, J ;
Horky, K ;
Aschermann, M .
JOURNAL OF HUMAN HYPERTENSION, 2002, 16 (08) :557-562
[16]  
Hwang SJ, 1997, CIRCULATION, V96, P4219
[17]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860
[18]  
Lip GYH, 1995, J HYPERTENS, V13, P1674
[19]  
Luscher TF, 1996, J HYPERTENS, V14, pS111
[20]   Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency [J].
Maschio, G ;
Alberti, D ;
Janin, G ;
Locatelli, F ;
Mann, JFE ;
Motolese, M ;
Ponticelli, C ;
Ritz, E ;
Zucchelli, P ;
Marai, P ;
Marcelli, D ;
Tentori, F ;
Andriani, M ;
Drago, G ;
Meneghel, G ;
Oldrizzi, L ;
Rugiu, C ;
Salvadeo, A ;
Villa, G ;
Picardi, L ;
Borghi, M ;
Moriggi, M ;
Vendramin, G ;
Fusaroli, M ;
Esposti, ED ;
Fabbri, A ;
Koch, KM ;
Frey, U ;
Schaeffer, J ;
Mann, J ;
Schweitzer, C ;
Zuccala, A ;
Gaggi, R ;
Stahl, R ;
Blaser, C ;
Rivolta, E ;
Buccianti, G ;
Gastaldi, L ;
Baratelli, M ;
Ducret, F ;
Pointet, P ;
Sterzel, R ;
Oberdorf, E ;
Pedrini, L ;
Faranna, P ;
Cairo, G ;
Ferrari, L ;
Albertazzi, A ;
Cappelli, P ;
Cantu, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (15) :939-945